ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data

SHANGHAIBIO BRINGS INGENUITY SOLUTIONS TO GROWING CHINESE MARKET

SHANGHAI, Sept. 5, 2012 /PRNewswire/ -- ShanghaiBio Corporation and Ingenuity® Systems have signed a collaboration agreement enabling ShanghaiBio Corporation to extend its current lab service offering to include Ingenuity solutions for downstream analysis and interpretation of genomics data. ShanghaiBio Corporation will complement their sequencing, genotyping and gene expression lab services by creating a bundled solution with Ingenuity's applications, which combine analytics and biomedical content to help get actionable insights from experiments.

ShanghaiBio Corporation, one of the leading genomics and biomarker service providers with all integrated microarray/next-generation sequencing/PCR/biobanking/pathology capabilities based in China and US, supports global pharmaceutical and biotechnology companies' and academic institutes' drug discovery efforts specifically in the areas of translational medicine and systems biology.  By offering Ingenuity products, ShanghaiBio Corporation supports the complete workflow from study design to bioinformatic analysis, providing its customers with high-quality data and easily interpretable results.

Jason Jin, CEO of ShanghaiBio Corporation, stated, "China is rapidly expanding its investment in the innovative life sciences, drug R&D, and molecular diagnostics sectors. Many organizations including pharmaceutical companies, biotech firms and universities have growing programs for translational medicine research and are faced with analyzing and understanding complex data. With Ingenuity's solutions, we are helping our customers rapidly obtain a detailed assessment of their data so they can move to the next phase of their research."

High throughput experiments generate a significant amount of data, and obtaining insights from that data can be a time-consuming, laborious process. Ingenuity's suite of products, based on the Ingenuity Knowledge Base repository of biological interactions and functional annotations created from the peer-reviewed literature, help researchers interpret the biological meaning of their data.

Dr. Hong Wang, a ShanghaiBio's collaborator and Assistant Professor from Rutgers University, explained, "The Ingenuity iReport analysis tool is essential in helping us understand the biological implications for our gene expression research projects. It is easy to use, and we can get the result within a few hours after we submit the raw data."

About Ingenuity® Systems

Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. For more information visit: www.ingenuity.com

About ShanghaiBio Corporation

ShanghaiBio Corporation is a leading biotech with lab operations in Shanghai and New Jersey. ShanghaiBio performs total genomics solution services for translational medicine focusing on biobanking, Microarray, Next Generation Sequencing (NGS), and biomarker assay development and companion diagnostics for personalized medicine. For more information, please visit www.ShanghaiBio.com or contact us at [email protected].

SOURCE ShanghaiBio Corporation

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.